Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C

Julien Vergniol, Jérôme Boursier, Clélia Coutzac, Sandrine Bertrais, Juliette Foucher, Camille Angel, Faiza Chermak, Isabelle Fouchard Hubert, Wassil Merrouche, Frédéric Oberti, Victor Lédinghen, Paul Calès – 12 February 2014 – No data are available about the prediction of long‐term survival using repeated noninvasive tests of liver fibrosis in chronic hepatitis C (CHC). We aimed to assess the prognostic value of 3‐year liver stiffness measurement (LSM), aspartate aminotransferase to platelet ratio index (APRI), and fibrosis 4 (FIB‐4) evolution in CHC.

High‐fat diet triggers Mallory‐Denk body formation through misfolding and crosslinking of excess keratin 8

Ozlem Kucukoglu, Nurdan Guldiken, Yu Chen, Valentyn Usachov, Amin El‐Heliebi, Johannes Haybaeck, Helmut Denk, Christian Trautwein, Pavel Strnad – 12 February 2014 – Mallory‐Denk bodies (MDBs) are protein aggregates consisting of ubiquitinated keratins 8/18 (K8/K18). MDBs are characteristic of alcoholic and nonalcoholic steatohepatitis (NASH) and discriminate between the relatively benign simple steatosis and the more aggressive NASH.

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.

Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis

Ewa Wunsch, Jocelyn Trottier, Malgorzata Milkiewicz, Joanna Raszeja‐Wyszomirska, Gideon M. Hirschfield, Olivier Barbier, Piotr Milkiewicz – 12 February 2014 – Ursodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10‐15 mg/kg/day) were included.

Subscribe to